Answers are grounded in this paper and cite their sources.
Discovery and development of new drugs for the treatment of inflammatory bowel disease (IBD) has intensified significantly within the past decade. However, numerous hurdles affect the pace and efficiency with which new drugs are developed. On March 20, 2019 the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) held a meeting entitled “Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design” in Miami, Florida. In addition to IOIBD members and IBD specialists, representatives from both industry and regulatory agencies were invited to speak and provide expert opinions and perspectives on the current landscape, factors influencing the evolution of IBD clinical trial design and endpoints, and potential novel approaches that may advance the field.
No takes yet. Share an insight, caveat, or question.
Abreu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: